Kodiak Sciences Inc.

biotech company

KOD Nasdaq ISIN US50015M1099 SEC CIK 1468748 LEI 254900IXI5NI8C9OQE24
Follow Kodiak Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$66.2M −7.8% vs same quarter last year
EPS, diluted −$1.05 +9.5% vs same quarter last year
Operating cash flow −$43.9M −33.4% vs same quarter last year
Operating income −$67.1M −7.6% vs same quarter last year
Net income by quarter
−$44.1M
−$57.5M
−$54.3M
−$61.5M
−$56.7M
−$58.2M
−$65.6M
−$66.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
−$400M−$300M−$200M−$100M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$230M
FY24−$176.2M
FY23−$260.5M
FY22−$333.8M
FY21−$267M
FY20−$133.1M
FY19−$47.4M
FY18−$41.4M
FY17−$27.9M
FY16−$17.1M
FY15-
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$136.5M
FY24−$117.7M
FY23−$195.5M
FY22−$243.5M
FY21−$199.3M
FY20−$87.2M
FY19−$39.6M
FY18−$29.1M
FY17−$17.9M
FY16−$16.8M
FY15-
Returned to shareholdersDividends paid and shares bought back
$0$1K$2K$3K$4KFY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18$0
FY17$0
FY16$4K
FY15-